36 Results for "

cognitive decline

" in MedChemExpress (MCE) Product Catalog:
Products (36)

36 Results for "cognitive decline" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P990110
Synonyms: Mab158

Target:  

Amyloid-β

Research Areas:  

Neurological Disease

Lecanemab (Mouse IgG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IgG2a sequence. Lecanemab (Mouse IgG2a) almost abolishes accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IgG2a) holds promise for research in the field of Alzheimer's disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093A
CAS No.: 1422365-94-3
Purity:  99.88%
Synonyms: IM156; HL156A; HL271 acetate
Lixumistat (IM156) acetate is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat acetate strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat acetate exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093B
CAS No.: 1422365-93-2
Synonyms: IM156 free base; HL156A free base; HL271 free base
Lixumistat (IM156 free base) is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136093
CAS No.: 1422365-52-3
Purity:  99.25%
Synonyms: HL271; IM156 hydrochloride; HL156A hydrochloride
Research Areas:  

Neurological Disease

Lixumistat (IM156) hydrochloride is a potent and orally active AMPK activator and OXPHOS inhibitor. Lixumistat hydrochloride strongly activates AMPK, while it lacks the systemic metabolic regulatory effects of classic metformin, such as hypoglycemic and weight-lowering activities. Lixumistat hydrochloride exhibits significant therapeutic effects on cognitive decline associated with brain aging and pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-110291
CAS No.: 1240308-45-5
Purity:  ≥99.0%
Target:  

LPL Receptor

Research Areas:  

Neurological Disease

A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC50s of .362, >10, 0.006 μM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .
loading...
    loading...
Cat. No.: HY-W009081
CAS No.: 2433-96-7
Tricosanoic acid is an endogenous agonist of long-chain saturated fatty acids and free fatty acid receptor FFAR1, which can activate hair growth. Tricosanoic acid (C23:0) has the activity of improving cognitive function by regulating neuronal membrane fluidity, inhibiting neuroinflammatory response, participating in myelination and neuronal energy metabolism. Tricosanoic acid expression levels are low in the prefrontal cortex of Alzheimer's disease (AD) models; while better cognitive performance corresponds to higher serum concentration levels. Tricosanoic acid can be used as a biomarker for diseases related to cognitive decline .
loading...
    loading...
Cat. No.: HY-132806
CAS No.: 2230009-48-8
Purity:  99.93%
Synonyms: RG-7816; RO-7017773
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
loading...
    loading...
Cat. No.: HY-108667
CAS No.: 61368-63-6
TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .
loading...
    loading...
Cat. No.: HY-125931
CAS No.: 272786-64-8
Purity:  99.78%
Synonyms: DM232
Target:  

iGluR

Unifiram (DM232) is a AMPA receptor activator and cognitive enhancer. Unifiram activates the AMPA-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ 3H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .
loading...
    loading...
Cat. No.: HY-43515
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .
loading...
    loading...
Cat. No.: HY-17549
CAS No.: 63547-13-7
Synonyms: CRL 40028
Target:  

Adrenergic Receptor

Research Areas:  

Neurological Disease

Adrafinil (CRL 40028) is an orally active vigilance promoting agent. Adrafinil enhances central noradrenergic transmission, improves spontaneous activity, exploratory behavior, discriminative learning ability and response motivation, but impairs visuospatial working memory. Adrafinil antagonizes Prazosin (HY-B0193)-induced hypoactivity and hypothermia, exerts anticonvulsant effects, and induces sustained enhancement of high-frequency electrocortical activity. Adrafinil can be used for research on decreased alertness and specific cognitive deficits .
loading...
    loading...
Cat. No.: HY-P6292
CAS No.: 2724212-01-3
Research Areas:  

Neurological Disease Cancer

KS-133 is a bicyclic peptide with VIPR2 antagonistic activity that can cross the blood-brain barrier. KS-133 selectively blocks VIPR2-mediated Gq/Ca, Gs/cAMP, cAMP/PKA/ERK and PI3K/AKT/GSK3β signaling pathways. KS-133 inhibits VIPR2 agonist-induced CREB phosphorylation in the prefrontal cortex of mice. KS-133 shifts the polarization direction of macrophages toward M1. KS-133 attenuates cancer cell proliferation and reduces the cell cycle distribution level at the S-M phase. KS-133 exerts antitumor effects in a mouse model of colorectal cancer. KS-133 reverses cognitive decline in mouse models of psychiatric disorders. KS-133 can be used for research related to schizophrenia, colorectal cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-P99959
CAS No.: 2379805-59-9
Synonyms: MT-3921; rH116A3

Target:  

TGF-β Receptor

Research Areas:  

Neurological Disease

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments .
loading...
    loading...
Cat. No.: HY-N5130
CAS No.: 73166-28-6
Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC50 values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline .
loading...
    loading...
Cat. No.: HY-135741
CAS No.: 2012536-16-0
Purity:  98.77%
NYX-2925 is an orally active, blood-brain barrier-permeable NMDAR modulator, with EC50 values of 55 pM, 28 fM, 11 pM and 55 pM against NR2A, NR2B, NR2C and NR2D, respectively . NYX-2925 enhances synaptic plasticity, long-term potentiation, metaplasticity, structural plasticity, learning ability, memory capacity and circadian rhythm amplitude. NYX-2925 regulates the signaling pathways of Src kinase, EIF2, mTOR, CDK5 and protein kinase A (PKA). NYX-2925 increases the levels of PSD-95, GluA1, activated Src and synaptic GluN2B . NYX-2925 is used in the research of neuropathic pain, fibromyalgia, painful diabetic peripheral neuropathy, post-traumatic stress disorder, cognitive impairment, depression, age-related cognitive decline and NMDAR-mediated central nervous system diseases .
loading...
    loading...
Cat. No.: HY-W106057
CAS No.: 728-86-9
Target:  

11β-HSD

11β-HSD1-IN-7 (compound c10a) is a 11β HSD1 inhibitor with an IC50 value of 1.9 μM for human 11β HSD1. 11β-HSD1-IN-7 can be used for the research of diabetes and cognitive decline .
loading...
    loading...
Cat. No.: HY-151627
CAS No.: 859721-81-6
Target:  

11β-HSD

11β-HSD1-IN-11 (Compound c1a) is a competitive 11β-HSD1 inhibitor with IC50s of 0.34 μM and 0.13 μM against rat and human 11β-HSD1, respectively .
loading...
    loading...
Cat. No.: HY-113448
CAS No.: 7274-08-0
Purity:  99.82%
Synonyms: 20:3 (8Z,11Z,14Z) CE; 20:3 n-6 CE; 20:3 (8Z,11Z,14Z) Cholesterol Ester
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

Cholesteryl homo-γ-linolenate is a cholesterol ester. It accumulates in the adrenal gland of rabbits fed a diet high in linolenic acid.1 Levels of cholesteryl homo-γ-linolenate are decreased and positively correlate with cognitive decline in HIV-infected humans.
loading...
    loading...
Cat. No.: HY-W611371
CAS No.: 61694-81-3
Target:  

TRP Channel iGluR

Research Areas:  

Neurological Disease

FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 can be used for AD and ALS research .
loading...
    loading...
Cat. No.: HY-W129359
CAS No.: 386704-15-0
Target:  

11β-HSD

11β-HSD1-IN-8 (compound c6a) is a 11β HSD1 inhibitor with an IC50 value of 2.3 μM for human 11β HSD1. 11β-HSD1-IN-8 can be used for the research of diabetes and cognitive decline .
loading...
    loading...